Biosimilar Red Tape Elimination Act
- Bill Number
- H.R. 5526
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-19: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-05T08:07:12Z
AI-Generated Summary
Purpose of the Legislation
The Biosimilar Red Tape Elimination Act (H.R. 5526) aims to simplify the approval process for biosimilar biological products—versions of complex drugs derived from living organisms that are similar to an original "reference" product. It seeks to reduce unnecessary requirements for determining if a biosimilar can be automatically substituted for the reference product at pharmacies (a status called "interchangeability"), thereby speeding up market entry and potentially lowering drug costs for patients.
Key Provisions
- Deemed Interchangeability: Upon approval as biosimilar, the product is automatically considered interchangeable with the reference product, eliminating the need for additional studies or demonstrations beyond what's required for basic biosimilar approval.
- Transition Period: A 60-day window after enactment allows for a smooth shift. Products approved after this date are interchangeable immediately upon licensure (unless blocked by an existing exclusivity period). Products approved before are interchangeable starting on the transition date, subject to the same exceptions.
- Preservation of Exclusivity: Any unexpired exclusivity periods for the first interchangeable biosimilar (a 180-day market protection period) remain in place for products licensed before the Act's enactment.
- Guidance Updates: The Secretary of Health and Human Services (through the FDA) must update or revoke existing guidance documents on interchangeability within 18 months and issue new guidance on biosimilar approval data requirements. Final or revised versions follow public comment.
- Conforming Amendments: Updates related laws to remove references to separate interchangeability standards, ensuring consistency. For example, it clarifies that biosimilars do not trigger new pediatric study requirements unless they involve novel uses.
Significant Changes to Existing Law
- Amends Section 351(k) of the Public Health Service Act by removing the subsection on interchangeability requirements, streamlining the approval pathway so biosimilar licensure inherently includes interchangeability (with transition rules).
- Eliminates the need for applicants to prove "no differences" in safety, purity, or potency under varied conditions, which was a higher bar previously required for interchangeability.
- Preserves pre-Act exclusivity to avoid disrupting ongoing market protections but ends the separate "first interchangeable" exclusivity for future approvals.
- Modifies definitions and cross-references in the Public Health Service Act and Federal Food, Drug, and Cosmetic Act to align with the new deemed interchangeability approach.
Potential Impacts
- On Government Agencies: The FDA will face a lighter review burden for interchangeability, potentially allowing faster approvals and resource reallocation to other drug safety efforts. It must issue updated guidance within set timelines, which could involve administrative costs.
- On Citizens: Patients may benefit from quicker access to lower-cost biosimilars, reducing out-of-pocket drug expenses, especially for chronic conditions treated with biologics (e.g., insulin or cancer drugs). However, substitution without doctor input could raise concerns about individual responses to biosimilars.
- On International Relations: Minimal direct impact, though it could enhance U.S. competitiveness in global biologics markets by aligning with international standards for biosimilar approvals, potentially influencing trade in pharmaceuticals.
Main Stakeholders Affected
- Pharmaceutical Companies: Biosimilar developers gain easier market entry, boosting competition; originators of reference products may see reduced market exclusivity, potentially cutting revenues.
- Healthcare Providers and Pharmacists: Easier substitution at pharmacies streamlines dispensing but requires updated training on biosimilars.
- Patients and Consumers: Primary beneficiaries through potential cost savings and increased treatment options.
- FDA and Regulators: Must adapt processes and guidance, affecting approval workflows.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the balance between innovation incentives (via preserved exclusivity) and competition, without altering core biosimilar standards. Includes a "rules of construction" clause to prevent misinterpretation as weakening safety requirements, potentially limiting future lawsuits over approval rigor.
- Constitutional: No direct challenges; aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause.
- Political: Supports broader efforts to lower drug prices amid debates on healthcare affordability, but could face opposition from brand-name drug makers concerned about eroded protections. The bill's bipartisan introduction (by Reps. Pfluger and Landsman) suggests potential for cross-aisle appeal in a divided Congress.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Pfluger, August [R-TX-11]
Cosponsors (8)
Rep. Landsman, Greg [D-OH-1], Rep. Auchincloss, Jake [D-MA-4], Rep. Crenshaw, Dan [R-TX-2], Rep. Vasquez, Gabe [D-NM-2], Rep. Owens, Burgess [R-UT-4], Rep. Fine, Randy [R-FL-6], Rep. Moore, Blake D. [R-UT-1], Rep. Sorensen, Eric [D-IL-17]
Recent Actions
- 2025-09-19: Referred to the House Committee on Energy and Commerce.
- 2025-09-19: Introduced in House
- 2025-09-19: Introduced in House
Bill Versions
- Biosimilar Red Tape Elimination Act — issued 2025-09-19 — PDF (10 pages)